Innovent Biologics Inc (IVBXF PINK) stock market data APIs
$11.5959
0(0%)
as of January 8, 2026
Try our APIs with
free plan!
Innovent Biologics Inc Financial Data Overview
Price chart is built with
Anychart
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Prev. Close
11.5959
Open
11.5959
High
11.5959
Low
11.5959
52 wk Range
3.9128-15.12
Market Cap
19 875 M
P/E Ratio
115.5
Shares Outstanding
1 721 M
Revenue
11 423 M
EPS
-0.0628
Beta
0.182
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Innovent Biologics Inc data using free add-ons & libraries
Get Innovent Biologics Inc Fundamental Data
Innovent Biologics Inc Fundamental data includes:
- Net Revenue: 11 423 M
- EBITDA: 1 302 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Innovent Biologics Inc News
New
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Asian Market Value Stocks: 3 Companies Priced Below Estimated Worth
As Asian markets navigate a landscape marked by mixed performances across major indices, investors are increasingly focused on identifying opportunities within the region. In this context, undervalued...
Notable healthcare headlines for the week: UnitedHealth, Molina Healthcare, and Novo Nordisk in focus
Wall Street's major averages struggled to hold onto gains on Friday, with both the S&P 500 and the Nasdaq Composite seesawing on the first trading day of 2026. The benchmark S&P 500 ended +0.2%, whil...
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 31.6%
As Asian markets navigate a landscape marked by cautious optimism, with indices like Japan's Nikkei 225 and China's CSI 300 showing gains amid global economic shifts, investors are increasingly on the...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
